(Total Views: 299)
Posted On: 03/12/2019 6:35:11 PM
Post# of 72443
What awaits Kevetrin in the near term? What would a deal look like if we cut one now? Let's look at some comps.
https://investorshub.advfn.com/boards/read_ms...=145781762
$80M upfront on 2 preclinical targets
$640M upfront + $1.5B milestones on 1 phase 1 PD-1 copycat
$150M upfront + $2.4B milestones on 10 preclinical targets
$225M upfront + $2.4B milestones on two phase 1 targets
$80M upfront + $2.8B milestones on a grab bag of preclinical targets
$200M upfront + $2.8B milestones on four preclinical targets
Kevetrin could likely do a deal worth far more than our current market cap of $25M. The comps above should ease the worries of even those who are terribly distraught about only have 2 patients (both successful) in the phase 2 trial.
https://investorshub.advfn.com/boards/read_ms...=145781762
$80M upfront on 2 preclinical targets
$640M upfront + $1.5B milestones on 1 phase 1 PD-1 copycat
$150M upfront + $2.4B milestones on 10 preclinical targets
$225M upfront + $2.4B milestones on two phase 1 targets
$80M upfront + $2.8B milestones on a grab bag of preclinical targets
$200M upfront + $2.8B milestones on four preclinical targets
Kevetrin could likely do a deal worth far more than our current market cap of $25M. The comps above should ease the worries of even those who are terribly distraught about only have 2 patients (both successful) in the phase 2 trial.
(2)
(0)Scroll down for more posts ▼
